The role of plasmacytoid dendritic cells in corneal immunity
浆细胞样树突状细胞在角膜免疫中的作用
基本信息
- 批准号:10640026
- 负责人:
- 金额:$ 50.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdoptive TransferAffectAllogenicAnti-Inflammatory AgentsAntigen PresentationAntigen Presentation PathwayAntigen-Presenting CellsAntigensAreaAutoimmuneBone MarrowCandidate Disease GeneCell CommunicationCellsChimera organismClinicalCoculture TechniquesCommunicable DiseasesConfocal MicroscopyCorneaCorneal DiseasesCorneal InjuryCorneal OpacityDataDendritic CellsDevelopmentDiseaseDisease ProgressionDry Eye SyndromesEndowmentEsthesiaFeasibility StudiesFibrin Tissue AdhesiveGene SilencingGenerationsGrantHerpesvirus 1Herpetic KeratitisHomeostasisImmuneImmune System DiseasesImmune responseImmunityInfectionInflammationInflammation ProcessInflammatoryInterferon Type IIInterleukin-10InvestigationKeratitisKeratoplastyKineticsLabelLeucocytic infiltrateLeukocytesLymphocyteMaintenanceMeasuresMediatingModelingMolecularNatural ImmunityNerveOutcomePropertyRegulatory T-LymphocyteRoleSeveritiesSeverity of illnessSimplexvirusStainsSterilitySurgical suturesSurvival RateT-Cell ProliferationT-LymphocyteTLR7 geneTNF geneTissuesTopical applicationTransforming Growth Factor betaTransgenic MiceTreatment EfficacyViralVirus Diseasesadaptive immune responseadaptive immunityadvanced diseasecandidate identificationclinically relevantcytokinedensitydraining lymph nodeeffector T cellexperimental studyimmune modulating agentsimmunoregulationimprovedin vivomultiphoton microscopynovelnovel strategiesphenotypic biomarkerprotein expressionreceptorrecruitside effectsingle cell sequencingsingle-cell RNA sequencingspatiotemporaltransplant modeluptake
项目摘要
SUMMARY
The cornea is among the few tissues that enjoy immune privilege, however, corneal immune privilege is
not absolute. In many corneal diseases, including infectious keratitis, dry eye disease, and corneal
injuries, infiltrating leukocytes can advance disease progression. Our preliminary results suggest that
plasmacytoid dendritic cells (PDCs), which reside in the cornea during steady state, actively participate
in the maintenance of corneal immune homeostasis, as their depletion leads to enhanced corneal
leukocyte infiltration and amplified adaptive immune responses in draining lymph nodes (dLNs). Thus, in
this application, we propose to evaluate the significance of PDCs in the maintenance of tolerance and
the mechanisms through which PDCs contribute to corneal immune homeostasis. We will identify
potential candidates through single cell sequencing of PDCs. We aim to study the role of PDCs in
mediating multiple steps involved in the process of inflammation, from leukocyte recruitment to the
cornea, antigen uptake and processing by antigen presenting cells, their egress to, and antigen
presentation in dLNs, and priming of T cells. Additionally, we have observed that PDCs interact directly
with T cells in the dLNs, and support development and stabilization of regulatory T cell (Tregs),
important immunosuppressive lymphocytes. We aim to analyze the molecular mechanisms by which
PDCs induce and maintain Tregs, as well as examine the clinical utility of adoptive transfer of PDC-
induced Tregs in infectious keratitis, dry eye disease and corneal transplantation. We also propose to
study the feasibility, efficacy, and potential local and systemic side effects of local adoptive transfer of
PDCs to the cornea for the treatment of immune and inflammatory diseases. Next, we aim to evaluate
therapeutic efficacy of local adoptive transfer of PDCs or application of PDC secretome in limiting clinical
severity of the disease, infiltration of leukocytes, disease progression, and complications in models of
dry eye disease and herpes simplex keratitis. This application proposes a paradigm shift on how PDCs
modulate immunity, and could result in the introduction of new immunomodulatory therapeutic
avenues for ocular as well as systemic inflammatory, autoimmune, alloimmune and infectious diseases.
摘要
角膜是少数享有免疫豁免权的组织之一,然而,角膜免疫豁免权是
不是绝对的。在许多角膜疾病中,包括传染性角膜炎、干眼病和角膜
损伤、白细胞的渗入会加速疾病的进展。我们的初步结果表明
稳定状态下驻留在角膜中的浆细胞样树突状细胞(PDCs)积极参与
在维持角膜免疫动态平衡方面,因为它们的耗尽导致角膜增强
引流淋巴结(DLN)中的白细胞浸润和放大的获得性免疫反应。因此,在
在这一应用中,我们建议评估PDCs在维持耐受性和
PDCs促进角膜免疫动态平衡的机制。我们将确定
通过对PDCs的单细胞测序获得潜在的候选者。我们的目标是研究PDC在
调节炎症过程中的多个步骤,从白细胞募集到
角膜,抗原提呈细胞的抗原摄取和处理,它们的出口和抗原
在DLN中的呈现,以及T细胞的启动。此外,我们还观察到PDC直接相互作用
在DLN中有T细胞,并支持调节性T细胞(Tregs)的发育和稳定,
重要的免疫抑制淋巴细胞。我们的目标是分析其分子机制
PDC诱导和维持Tregs,以及检测PDC过继转移的临床效用-
在感染性角膜炎、干眼病和角膜移植中诱导Tregs。我们还建议
研究就地收养转移的可行性、有效性以及潜在的局部和全身副作用。
PDCs到角膜治疗免疫性和炎症性疾病。接下来,我们的目标是评估
局部过继转移PDCs或应用PDC分泌组限制临床的疗效
模型中疾病的严重性、白细胞的渗透、疾病的进展和并发症
干眼症和单纯疱疹病毒性角膜炎。此应用程序提出了PDC的范式转变
调节免疫,并可能导致新的免疫调节疗法的引入
眼科和全身炎症、自身免疫、同种免疫和传染病的途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pedram Hamrah其他文献
Pedram Hamrah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pedram Hamrah', 18)}}的其他基金
Central and Peripheral Mechanisms of Corneal Pain
角膜疼痛的中枢和外周机制
- 批准号:
10707313 - 财政年份:2022
- 资助金额:
$ 50.76万 - 项目类别:
Central and Peripheral Mechanisms of Corneal Pain
角膜疼痛的中枢和外周机制
- 批准号:
10595408 - 财政年份:2022
- 资助金额:
$ 50.76万 - 项目类别:
Discovery of the Biomarker Signature for Neuropathic Corneal Pain
神经性角膜疼痛生物标志物特征的发现
- 批准号:
10617101 - 财政年份:2019
- 资助金额:
$ 50.76万 - 项目类别:
The role of plasmacytoid dendritic cells in ocular angiogenesis
浆细胞样树突状细胞在眼血管生成中的作用
- 批准号:
9318784 - 财政年份:2017
- 资助金额:
$ 50.76万 - 项目类别:
The role of plasmacytoid dendritic cells in ocular angiogenesis
浆细胞样树突状细胞在眼血管生成中的作用
- 批准号:
9893891 - 财政年份:2017
- 资助金额:
$ 50.76万 - 项目类别:
Role of plasmacytoid dendritic cells in corneal nerve health and regeneration
浆细胞样树突状细胞在角膜神经健康和再生中的作用
- 批准号:
9208776 - 财政年份:2016
- 资助金额:
$ 50.76万 - 项目类别:
The role of plasmacytoid dendritic cells in corneal immunity
浆细胞样树突状细胞在角膜免疫中的作用
- 批准号:
9329957 - 财政年份:2016
- 资助金额:
$ 50.76万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 50.76万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 50.76万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 50.76万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 50.76万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 50.76万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 50.76万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 50.76万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 50.76万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 50.76万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 50.76万 - 项目类别:














{{item.name}}会员




